Iluvien™（醋酸氟轻松0.19毫克玻璃体内植入剂）治疗糖尿病性黄斑水肿的综述
Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review.
作者信息
Fusi-Rubiano William, Blow Rebecca R, Lane Mark, Morjaria Rupal, Denniston Alastair K
机构信息
Sandwell and West Birmingham NHS Trust, Dudley Road, Birmingham, UK.
Lion Health Medical Centre, Lowndes Road, Stourbridge, UK.
出版信息
Ophthalmol Ther. 2018 Dec;7(2):293-305. doi: 10.1007/s40123-018-0145-7. Epub 2018 Sep 18.
Abstract
Diabetic macular edema (DMO) is a leading cause of blindness in the working age population. Although anti-vascular endothelial growth factor (VEGF) therapy provided a major advance in treatment of DMO for many patients, there is a significant proportion of patients who maintain persistent DMO and have minimal response to anti-VEGF treatment. Iluvien (fluocinolone acetonide 0.19 mg [FAc]) is an important additional treatment option for DMO. In this review we describe the clinical context and the evidence for the use of the FAc implant in treating DMO, from pilot to randomized controlled studies, to later phase real world data. These studies indicate that the FAc implant is effective, well tolerated and a cost-effective option in the treatment of insufficiently responsive DMO.
摘要
糖尿病性黄斑水肿（DMO）是劳动年龄人群失明的主要原因。尽管抗血管内皮生长因子（VEGF）疗法在许多患者的DMO治疗中取得了重大进展，但仍有相当一部分患者的DMO持续存在，且对抗VEGF治疗反应甚微。Iluvien（醋酸氟轻松0.19毫克[FAc]）是DMO的一种重要的额外治疗选择。在本综述中，我们描述了从试点研究到随机对照研究，再到后期阶段真实世界数据的临床背景以及使用FAc植入物治疗DMO的证据。这些研究表明，FAc植入物在治疗反应不足的DMO方面是有效的、耐受性良好且具有成本效益的选择。
相似文献
1
Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review.Iluvien™（醋酸氟轻松0.19毫克玻璃体内植入剂）治疗糖尿病性黄斑水肿的综述
Ophthalmol Ther. 2018 Dec;7(2):293-305. doi: 10.1007/s40123-018-0145-7. Epub 2018 Sep 18.
2
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.治疗糖尿病性黄斑水肿（DMO）：英国真实世界中0.19毫克醋酸氟轻松玻璃体内植入剂（Iluvien™）2年的临床疗效
BMC Ophthalmol. 2018 Feb 27;18(1):62. doi: 10.1186/s12886-018-0726-1.
3
Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.氟轻松醋酸酯植入剂（ILUVIEN®）治疗英国慢性糖尿病性黄斑水肿患者的成本效益分析，这些患者对现有疗法反应不足。
BMC Health Serv Res. 2019 Jan 9;19(1):22. doi: 10.1186/s12913-018-3804-4.
4
Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience.玻璃体内注射曲安奈德（FAc）（ILUVIEN™）治疗既往治疗无效的糖尿病性黄斑水肿（DMO）患者的临床疗效：曼彻斯特经验
Ophthalmol Ther. 2019 Sep;8(3):477-484. doi: 10.1007/s40123-019-0197-3. Epub 2019 Jul 15.
5
Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.玻璃体内注射曲安奈德植入物（ILUVIEN®）治疗糖尿病性黄斑水肿：文献综述
J Int Med Res. 2019 Jan;47(1):31-43. doi: 10.1177/0300060518816884. Epub 2018 Dec 16.
6
Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.接受玻璃体内注射曲安奈德（FAc）植入物治疗的糖尿病性黄斑水肿有晶状体患者的长期预后。
Eye (Lond). 2015 Sep;29(9):1173-80. doi: 10.1038/eye.2015.98. Epub 2015 Jun 26.
7
Intravitreal Fluocinolone Acetonide Implant (ILUVIEN) for the Treatment of Retinal Conditions. A Review of Clinical Studies.玻璃体腔内氟轻松醋酸酯植入物（ILUVIEN）治疗视网膜疾病。临床研究综述。
Drug Des Devel Ther. 2023 Mar 30;17:961-975. doi: 10.2147/DDDT.S403259. eCollection 2023.
8
Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN): A Review in Diabetic Macular Edema.氟轻松玻璃体内植入剂 0.19 毫克（ILUVIEN）：用于糖尿病性黄斑水肿的评价。
Drugs. 2017 Apr;77(5):575-583. doi: 10.1007/s40265-017-0722-4.
9
A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series.一种新型玻璃体内注射曲安奈德植入物（Iluvien(®)）治疗对其他药物治疗方案反应欠佳的慢性糖尿病性黄斑水肿患者：病例系列
Clin Ophthalmol. 2015 May 4;9:801-11. doi: 10.2147/OPTH.S79785. eCollection 2015.
10
Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.氟轻松玻璃体内植入剂（Iluvien®）：治疗糖尿病性黄斑水肿。
Drugs. 2013 Feb;73(2):187-93. doi: 10.1007/s40265-013-0010-x.
引用本文的文献
1
Role of EYP-1901 in neovascular age-related macular degeneration and diabetic eye diseases: review of Phase I/II trials.EYP-1901 在新生血管性年龄相关性黄斑变性和糖尿病眼病中的作用：I/II 期临床试验综述。
Ther Deliv. 2024;15(11):829-843. doi: 10.1080/20415990.2024.2406226. Epub 2024 Oct 3.
2
The Treatment of Diabetic Retinal Edema with Intravitreal Steroids: How and When.玻璃体内注射类固醇治疗糖尿病性视网膜水肿：方法与时机
J Clin Med. 2024 Feb 26;13(5):1327. doi: 10.3390/jcm13051327.
3
Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study.在认为对现有疗法反应不足的糖尿病性黄斑水肿患者中，氟轻松醋酸酯玻璃体内植入物的有效性和安全性（REACT）：一项前瞻性、非随机和多中心研究。
Int Ophthalmol. 2023 Dec;43(12):4639-4649. doi: 10.1007/s10792-023-02864-2. Epub 2023 Sep 12.
4
Trends in Ophthalmological Patents, 2005-2020.2005-2020 年眼科专利趋势。
J Ocul Pharmacol Ther. 2023 Jul;39(6):365-370. doi: 10.1089/jop.2022.0185. Epub 2023 May 16.
5
Visual function and retinal morphological changes after single suprachoroidal delivery of fluocinolone acetonide (Iluvien®) implant in eyes with chronic diabetic macular edema.单次脉络膜上腔注射曲安奈德（Iluvien®）植入物治疗慢性糖尿病性黄斑水肿后眼睛的视觉功能和视网膜形态学变化
Int J Retina Vitreous. 2023 Mar 29;9(1):20. doi: 10.1186/s40942-023-00458-9.
6
Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update.基于纳米技术的眼部疾病诊断和治疗的最新进展，综述与更新。
J Nanobiotechnology. 2022 Aug 2;20(1):361. doi: 10.1186/s12951-022-01567-7.
7
Aqueous Humor Analyses in Patients with Diabetic Retinopathy Who Had Undergone Panretinal Photocoagulation.糖尿病视网膜病变患者行全视网膜光凝术后房水分析。
J Diabetes Res. 2022 Jun 20;2022:1897344. doi: 10.1155/2022/1897344. eCollection 2022.
8
The effect of pars plana vitrectomy with internal limiting membrane peeling on the durability of the intravitreal dexamethasone implant in the treatment of diabetic macular edema.玻璃体平坦部玻璃体切除术联合内界膜剥除术对玻璃体内地塞米松植入物治疗糖尿病性黄斑水肿疗效持久性的影响
Am J Ophthalmol Case Rep. 2022 Feb 17;26:101401. doi: 10.1016/j.ajoc.2022.101401. eCollection 2022 Jun.
9
In vitro dissolution testing models of ocular implants for posterior segment drug delivery.用于后段药物递送的眼部植入物的体外溶解测试模型。
Drug Deliv Transl Res. 2022 Jun;12(6):1355-1375. doi: 10.1007/s13346-021-01043-z. Epub 2021 Aug 11.
10
Real-World Outcomes in Diabetic Macular Edema for the 0.2 µg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK.0.2微克/天氟轻松丙酮化物植入剂治疗糖尿病性黄斑水肿的真实世界疗效：来自英国中部地区的病例系列
Clin Ophthalmol. 2021 Jul 7;15:2935-2943. doi: 10.2147/OPTH.S283561. eCollection 2021.
本文引用的文献
1
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.治疗糖尿病性黄斑水肿（DMO）：英国真实世界中0.19毫克醋酸氟轻松玻璃体内植入剂（Iluvien™）2年的临床疗效
BMC Ophthalmol. 2018 Feb 27;18(1):62. doi: 10.1186/s12886-018-0726-1.
2
Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.玻璃体内注射190μg醋酸氟轻松植入剂（ILUVIEN®）治疗慢性糖尿病性黄斑水肿：玻璃体切割术眼与未行玻璃体切割术眼的比较
Ophthalmic Res. 2018;59(2):68-75. doi: 10.1159/000484091. Epub 2017 Dec 16.
3
DISLODGEMENT OF FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT INTO THE INFUSION CANNULA DURING VITRECTOMY FOR RETINAL DETACHMENT.在视网膜脱离的玻璃体切除术中，氟轻松醋酸酯眼内植入物从灌注套管中脱出。
Retin Cases Brief Rep. 2020 Summer;14(3):215-217. doi: 10.1097/ICB.0000000000000678.
4
Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective Cost Analysis Study.将难治性糖尿病性黄斑水肿患者转换为玻璃体内注射氟轻松丙酮化物（Iluvien）所显示的真实世界成本节约：一项回顾性成本分析研究
Ophthalmol Ther. 2018 Jun;7(1):75-82. doi: 10.1007/s40123-017-0114-6. Epub 2017 Nov 10.
5
Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.氟轻松醋酸酯 190µg 玻璃体腔内植入物治疗糖尿病黄斑水肿前后的视网膜厚度变化模式。
Curr Med Res Opin. 2017 Oct;33(sup2):33-43. doi: 10.1080/03007995.2017.1366662. Epub 2017 Sep 7.
6
Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema.评估氟轻松醋酸酯 190µg 玻璃体腔内植入物在糖尿病性黄斑水肿患者中的常规临床疗效。
Curr Med Res Opin. 2017 Oct;33(sup2):5-17. doi: 10.1080/03007995.2017.1366645. Epub 2017 Sep 7.
7
Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.评估氟轻松醋酸酯 190µg 玻璃体腔内植入物治疗糖尿病性黄斑水肿的临床疗效：研究眼与对侧眼比较。
Curr Med Res Opin. 2017 Oct;33(sup2):19-31. doi: 10.1080/03007995.2017.1366659. Epub 2017 Sep 7.
8
Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom.英国0.2μg/天氟轻松丙酮奈德玻璃体内植入剂（ILUVIEN）的真实世界经验。
Eye (Lond). 2017 Dec;31(12):1707-1715. doi: 10.1038/eye.2017.125. Epub 2017 Jul 24.
9
Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA).欧洲视网膜专家协会（EURETINA）糖尿病性黄斑水肿管理指南
Ophthalmologica. 2017;237(4):185-222. doi: 10.1159/000458539. Epub 2017 Apr 20.
10
Real-Life ILUVIEN (Fluocinolone Acetonide) Case Study: Rapid Drying of the Macula and Improved Vision within 2 Years after Therapy Initiation.真实世界中ILUVIEN（曲安奈德）病例研究：治疗开始后2年内黄斑快速干燥且视力改善。
Case Rep Ophthalmol. 2016 Dec 28;7(3):301-307. doi: 10.1159/000452883. eCollection 2016 Sep-Dec.
Zotero 插件